Heat shock protein 10(Invion Ltd.)(Heat shock protein 10(Invion Ltd.)) - 在研适应症：溃疡性结肠炎，多发性硬化症，银屑病_专利_临床

概要

基本信息

药物类型

重组蛋白

别名

Chaperonin 10、Chaperonin-10、Heat shock protein 10

+ [10]

靶点-

作用机制

免疫调节剂

治疗领域

免疫系统疾病神经系统疾病消化系统疾病+ [2]

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

6

项与 Heat shock protein 10(Invion Ltd.) 相关的临床试验

NCT01838694 / Completed临床1/2期

Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.

The primary objective of the study is to evaluate the safety, tolerability, and efficacy of 4 weeks intravenous treatment with Cpn10 in subjects with mild to moderate active SLE.

开始日期2013-07-01

申办/合作机构

Invion Ltd.

ACTRN12609000078257 / Suspended临床2期

A mulit-centre, long term follow-up, open label trial to assess the efficacy and safety of Cpn10 in subjects with rheumatoid arthritis (Protocol number CBIO2008-01)

开始日期2009-01-05

申办/合作机构

CBio Ltd.

ACTRN12608000208303 / Active, not recruiting临床2期

A multi-centre, randomised, double blind, placebo-controlled, parallel group, phase IIa clinical trial to assess the efficacy and safety of Cpn10 administered as twice weekly subcutaneous injections in subjects with Rheumatoid Arthritis

开始日期2008-05-01

申办/合作机构

CBio Ltd.

100 项与 Heat shock protein 10(Invion Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Heat shock protein 10(Invion Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Heat shock protein 10(Invion Ltd.) 相关的专利（医药）

登录后查看更多信息

15

项与 Heat shock protein 10(Invion Ltd.) 相关的文献（医药）

2016-05-01·Bulletin du Cancer4区 · 医学

Mise au point sur les glioblastomes : des thérapies ciblant les cellules tumorales aux thérapies ciblant les cellules immunitaires

4区 · 医学

Review

作者: Armand, Jean-Pierre ; Massard, Christophe ; Schernberg, Antoine ; Dumont, Sarah ; Dhermain, Frédéric ; Marabelle, Aurélien ; Deutsch, Eric

INTRODUCTIONGlioblastoma (GBM) is associated with a poor prognosis. This review will discuss different directions of treatment, mostly regarding immunotherapies and combinatorial approaches.DEVELOPMENTStandard treatment for newly diagnosed GBM is maximal and safe surgical resection followed by concurrent radiochemotherapy (RCT) based on temozolomide, allowing 14.6 months median survival. Nowadays, no combination with molecular-targeted therapy had significantly improved prognosis. Phases I and II data are emerging, highlighting the potential efficacy of associations with other therapies. Studies have suggested the potential of targeting tumor stem cells, at less partially responsible for resistance to RCT. There is now some evidence that immunotherapy is also relevant for brain tumors. Treatment strategies have mainly explored vaccines strategies, such as the dendritic cell, heat shock protein or EGFRvIII vaccines. Of the work initiated in melanoma, immune checkpoints inhibitors have exhibited stimulating results. Others trials have demonstrated potential of autologous stimulated lymphocytes. Moreover, strong data indicates that radiation therapy has the potential to promote immunogenicity and create a sort of in situ personalized vaccine.CONCLUSIONThese data provide strong evidence to support the potential of associating combinatorial targeted and/or immunotherapeutic regimens in patients with GBM that may change patient outcome.

2015-02-01·Experimental and Therapeutic Medicine4区 · 医学

Recombinant Cpn 0810 stimulates proinflammatory cytokine expression and apoptosis in human monocytes

4区 · 医学

Article

作者: Chen, Yuyu ; Wu, Yimou ; Liu, Liangzhuan ; Chen, Lili ; You, Xiaoxing ; Wu, Baiping ; Zhang, Qiugui

The aim of the present study was to express the recombinant Chlamydophila pneumoniae (C. pneumoniae) protein, Cpn 0810, in Escherichia coli (E. coli) BL21, and investigate the effects of Cpn 0810 on inflammatory and apoptotic processes in human monocytic (THP-1) cells. An ELISA was performed to detect the levels of the proinflammatory cytokines, tumor necrosis factor (TNF)-α and interleukin (IL)-6. In addition, Hoechst 33258 staining and annexin V binding analyses were performed to measure the rates of apoptosis. Purified glutathione S-transferase (GST)-Cpn 0810 recombinant proteins were obtained from the E. coli BL21 cells carrying the pGEX6p-2/Cpn 0810 plasmid, and were shown to stimulate the expression of TNF-α and IL-6 in the THP-1 cells in a dose- and time-dependent manner. TNF-α and IL-6 levels peaked at 24 h after GST-Cpn 0810 stimulation. Furthermore, GST-Cpn 0810 significantly promoted the apoptosis of THP-1 cells. In conclusion, recombinant GST-Cpn 0810 was shown to stimulate the expression of TNF-α and IL-6, inhibit proliferation and induce apoptosis in THP-1 cells. Therefore, Cpn 0810 may interact with host cells following C. pneumoniae infection, functioning as an important pathogenic factor.

2012-04-01·Nephrology Dialysis Transplantation2区 · 医学

Recombinant chaperonin 10 suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice

2区 · 医学

Article

作者: Onkar P. Kulkarni ; Claudia Kantner ; Miklós Sárdy ; Hans-Joachim Anders ; Richard Brown ; Daniel Lambert ; Mi Ryu ; Dean Naylor

BACKGROUNDSystemic lupus erythematosus (SLE) is still treated with global immunosuppressants with serious toxicities. We hypothesized that endogenous immunosuppressive molecules might be able to control SLE manifestations more specifically. Heat shock protein 10, or chaperonin 10 (Cpn10), is a secretory molecule that can suppress innate and adaptive immunity.METHODSRecombinant human Cpn10 (100 μg per mouse) was given intraperitoneally to healthy-appearing female MRL-(Fas)lpr mice from 12 to 22 weeks of age. At the age of 22 weeks, mice were analysed for treatment outcome by harvesting organs, plasma and urine.RESULTSCpn10 entirely prevented cutaneous lupus lesions as compared to vehicle-treated mice. Cpn10 also suppressed lupus nephritis as evident from serum creatinine levels, albuminuria and the scores of disease activity and chronicity. Autoimmune lung disease was unaffected by Cpn10 treatment while overall survival of mice was prolonged. Cpn10 did not have any major effects on either dendritic cell or B-cell counts except T cells in spleen, plasma interferon-gamma, tumour necrosis factor-alpha, interleukin-10, anti-nuclear autoantibody levels or markers of lymphoproliferation.CONCLUSIONSIn summary, recombinant Cpn10 selectively prevents cutaneous lupus and suppresses nephritis in MRL-(Fas)lpr mice without affecting the underlying systemic autoimmune process. Hence, Cpn10 might be useful for the treatment of skin and kidney manifestations of SLE.

100 项与 Heat shock protein 10(Invion Ltd.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
斑块状银屑病	临床3期	澳大利亚	Invion Ltd.	-
溃疡性结肠炎	临床2期	-	Invion Ltd.	-
多发性硬化症	临床2期	-	Invion Ltd.	-
银屑病	临床2期	-	Invion Ltd.	-
类风湿关节炎	临床2期	-	Invion Ltd.	-
系统性红斑狼疮	临床2期	-	Invion Ltd.	-
溃疡性结肠炎	临床前	澳大利亚	-	-
多发性硬化症	临床前	澳大利亚	Invion Ltd.	-
类风湿关节炎	临床前	澳大利亚	Invion Ltd.	-
类风湿关节炎	临床前	新西兰	Invion Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01838694 (CTgov)	临床1/2期	系统性红斑狼疮	30	Placebo (Placebo)	願廠遞範鑰遞鬱窪鹽夢(憲鏇願齋鹽窪築憲膚願) = 鹹鹽觸糧襯積壓壓壓範選遞醖鏇獵淵蓋膚鹹遞 (範鬱窪膚製鏇醖壓蓋鑰, 鬱顧獵夢淵壓衊積餘壓 ~ 艱鹽鬱廠糧襯鑰選遞鬱) 更多	-	2017-01-30
				Ala-Cpn10 (Ala-Cpn10)	願鬱醖鹹觸鹽鹹襯衊願(繭獵鑰範鹹積鑰窪艱鹹) = 淵觸窪獵蓋築網網獵夢襯積醖膚範選淵壓繭廠 (築鹽顧網蓋衊淵網網憲, 廠鑰壓願範醖膚夢廠襯 ~ 憲觸遞廠襯構遞窪鹹簾) 更多